SARE

Sareum is a clinical-stage biotechnology company based in the UK that specializes in the development of small molecule therapeutics, particularly focused on the selective inhibition of Janus kinase 1 (JAK1) and Tyrosine kinase 2 (TYK2). The company's lead candidate, SDC-1801, is being developed for the treatment of autoimmune and inflammatory diseases, including psoriasis and lupus. Sareum also maintains a pipeline of oncology programs, including SDC-1802, which targets cancer through immune-oncology mechanisms. By leveraging its expertise in structural biology and medicinal chemistry, Sareum aims to provide highly selective treatments that minimize side effects associated with broader kinase inhibition.